GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » Cyclically Adjusted Revenue per Share

Heidelberg Pharma AG (LTS:0QW5) Cyclically Adjusted Revenue per Share : €0.25 (As of Feb. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Heidelberg Pharma AG's adjusted revenue per share for the three months ended in Feb. 2025 was €0.028. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.25 for the trailing ten years ended in Feb. 2025.

During the past 12 months, Heidelberg Pharma AG's average Cyclically Adjusted Revenue Growth Rate was -17.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -27.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -24.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Heidelberg Pharma AG was -19.60% per year. The lowest was -29.60% per year. And the median was -23.80% per year.

As of today (2025-05-25), Heidelberg Pharma AG's current stock price is €3.31. Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2025 was €0.25. Heidelberg Pharma AG's Cyclically Adjusted PS Ratio of today is 13.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Heidelberg Pharma AG was 14.00. The lowest was 1.60. And the median was 8.31.


Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Chart

Heidelberg Pharma AG Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.83 0.41 0.29 0.24

Heidelberg Pharma AG Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.30 0.25 0.24 0.25

Competitive Comparison of Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Heidelberg Pharma AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cyclically Adjusted PS Ratio falls into.


;
;

Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Heidelberg Pharma AG's adjusted Revenue per Share data for the three months ended in Feb. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=0.028/127.3575*127.3575
=0.028

Current CPI (Feb. 2025) = 127.3575.

Heidelberg Pharma AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201505 0.103 100.417 0.131
201508 0.036 100.617 0.046
201511 0.059 99.717 0.075
201602 0.040 99.317 0.051
201605 0.038 100.617 0.048
201608 0.014 101.017 0.018
201611 0.020 100.517 0.025
201702 0.035 101.217 0.044
201705 0.028 101.817 0.035
201708 0.036 102.617 0.045
201711 0.032 102.117 0.040
201802 0.022 102.317 0.027
201805 0.047 103.917 0.058
201808 0.036 104.517 0.044
201811 0.022 104.217 0.027
201902 0.038 103.817 0.047
201905 0.094 105.418 0.114
201908 0.086 106.018 0.103
201911 0.040 105.318 0.048
202002 0.052 105.618 0.063
202005 0.052 106.018 0.062
202008 0.138 106.018 0.166
202011 0.032 105.018 0.039
202102 0.012 107.018 0.014
202105 0.014 108.170 0.016
202108 0.009 109.118 0.011
202111 0.018 110.173 0.021
202202 0.021 111.754 0.024
202205 0.328 115.760 0.361
202208 0.095 116.709 0.104
202211 0.060 119.872 0.064
202302 0.044 121.454 0.046
202305 0.050 122.824 0.052
202308 0.048 123.878 0.049
202311 0.069 123.668 0.071
202402 0.028 124.511 0.029
202405 0.060 125.776 0.061
202408 0.026 126.198 0.026
202411 0.033 126.409 0.033
202502 0.028 127.358 0.028

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Heidelberg Pharma AG  (LTS:0QW5) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Heidelberg Pharma AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.31/0.25
=13.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Heidelberg Pharma AG was 14.00. The lowest was 1.60. And the median was 8.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Industry
Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines